Does quinolone- or macrolide-resistant Streptococcus agalactiae bacteremia affect patient outcome? A multicenter cohort study

Satoru Mitsuboshi; Junichiro Date; Naoki Tsuruma; Hirokazu Yamaga; Kazuya Watanabe; Hiroko Kijima; Manami Nakashita; Hiroki Hosokawa; Masami Tsugita

doi:10.7883/yoken.JJID.2020.589

This article has now been updated. Please use the final version.

Does quinolone- or macrolide-resistant Streptococcus agalactiae bacteremia affect patient outcome? A multicenter cohort study

Satoru Mitsuboshi, Junichiro Date, Naoki Tsuruma, Hirokazu Yamaga, Kazuya Watanabe, Hiroko Kijima, Manami Nakashita, Hiroki Hosokawa, Masami Tsugita

Author information

Keywords: Streptococcus agalactiae, quinolone, macrolide, resistance

JOURNAL FREE ACCESS Advance online publication

Article ID: JJID.2020.589

DOI https://doi.org/10.7883/yoken.JJID.2020.589

The final version of this article is now available: Vol. 74 (2021), No. 3 pp. 240-244

Details

Abstract

The prevalence of quinolone- and macrolide-resistant Group B Streptococcus (GBS) is increasing worldwide, but the relationship between GBS resistance to these antibiotics and patient outcome remains unclear. Therefore, we evaluated whether blood stream infection caused by quinolone- or macrolide-resistant GBS is associated with high mortality. Our findings in 77 patients with GBS bacteremia demonstrate that quinolone and macrolide resistance may not be risk factors for 30-day mortality.

Corresponding author

Register with J-STAGE for free!